Fragile X Syndrome

Abstract

Fragile X syndrome is the most common inherited cause of intellectual disability and the most common single-gene cause of autism. It arises when a CGG trinucleotide repeat in the FMR1 gene expands past about 200 copies, silencing the gene and cutting off its protein, FMRP — a brake on protein synthesis at the synapse. Its interest for cognitive psychology lies in the *shape* of the resulting profile: fragile X does not lower every ability uniformly but selectively impairs inhibitory and executive attention, sequential processing, and working memory, while sparing simultaneous processing, receptive vocabulary, and memory for meaning. This article sets out the genetics, the loss-of-function cascade from repeat to synapse, the uneven cognitive phenotype and its signature attention deficit, the premutation disorders, and what a single gene's silencing reveals about the architecture of mind.

Keywords: FMR1, trinucleotide repeat, cognitive phenotype, executive attention

Fragile X syndrome matters to cognitive psychology for the same reason Down syndrome does: it is a natural experiment in how one precisely specified genetic difference reshapes the mind. Here the difference is smaller still — not a whole extra chromosome but the runaway expansion of a single three-letter sequence, CGG, repeated too many times at the start of one gene on the X chromosome (Verkerk et al., 1991). From that one change flows a pattern of cognitive strengths and weaknesses that is neither random nor uniform, and it is that *structure* that makes the condition scientifically informative (Cornish et al., 2004).

The account below moves from what fragile X syndrome is and how the repeat expansion arises, through the molecular cascade that silences the gene, to the uneven cognitive profile and its signature deficit in inhibitory and executive attention, and then to development across the lifespan and the separate disorders that the smaller premutation can cause. The recurring theme, as with other genetic conditions, is dissociation: capacities that ordinary experience treats as one come conspicuously apart.

Figure 1

The CGG-Repeat Spectrum of the FMR1 Gene

What Fragile X Syndrome Is

Fragile X syndrome is the clinical condition that results when the FMR1 gene, near the tip of the long arm of the X chromosome, is switched off by an expanded CGG repeat, so that its protein product is no longer made. The name comes from the way the affected X chromosome appeared under early cytogenetic techniques: a constriction, or “fragile site,” at which the chromosome seemed almost to break (Sutherland & Hinton, 1981). It is the most common *inherited* cause of intellectual disability — Down syndrome is more common overall, but it is not usually inherited — and it is the most common known single-gene cause of autism (Hagerman et al., 2017). Newborn-screening studies place the full mutation at roughly one in 5,000 males (Coffee et al., 2009), with pooled epidemiological estimates in the same range (Hunter et al., 2014).

The single most important idea for understanding fragile X cognitively is the one it shares with other genetic syndromes: it does *not* impair the mind uniformly. Against a background of generally lowered measured intelligence, certain abilities stand out as relative strengths and others as disproportionate weaknesses (Cornish et al., 2004). This unevenness is the phenotype's most scientifically informative feature, because a cause that simply dimmed a single, undifferentiated faculty of intelligence could not produce it — the pattern shows that the mind is built from separable components that the loss of one protein touches to different degrees (Munir, Cornish, & Wilding, 2000).

Because fragile X is *X-linked*, its expression differs sharply between the sexes. Males have a single X chromosome, so a full mutation on it leaves them with essentially no FMRP and a fuller, more consistent presentation. Females have a second, usually unaffected X, and because one X is randomly inactivated in each cell, the amount of working protein varies; females are therefore affected more variably and, on average, more mildly (Loesch, Huggins, & Hagerman, 2004). And because the extra repeats are present from conception, fragile X is a *developmental* condition whose profile emerges over time rather than being fixed at birth (Cornish et al., 2013).

Core Features

The cognitive core of fragile X syndrome is a characteristic profile of relative strengths and weaknesses, and its single most distinctive element is an attention deficit. On the strength side, *simultaneous* processing (grasping a whole pattern at once), *receptive* vocabulary (the words a person understands), and memory for meaningful, associatively rich material are comparatively well preserved (Munir et al., 2000). On the weakness side, *sequential* processing (handling information in an ordered series), *working memory*, and above all *inhibitory and executive attention* — suppressing a prepotent response and controlling the focus of attention — are disproportionately poor (Cornish et al., 2004).

The inhibitory-attention deficit is the phenotype's signature because it is *disproportionate*: it is worse than the child's general level of delay would predict, whereas many other abilities track that general level. Careful neuropsychological work has shown that this is not mere slowness or a global deficit but a specific difficulty in inhibition and attentional control, dissociable from the relatively intact ability to hold a pattern as a whole (Munir et al., 2000). Establishing that a deficit is genuinely disproportionate, rather than simply part of an across-the-board delay, requires comparing a child not with age peers but with younger children matched on overall mental age — the methodological move worked through in the example below (Cornish et al., 2004).

A second core feature is the tie between this attention profile and behaviour. The difficulty inhibiting responses and sustaining controlled attention shades into the hyperactivity, impulsivity, and distractibility that are common in the syndrome, and into the social anxiety and gaze avoidance that colour its behavioural phenotype (Cordeiro, Ballinger, Hagerman, & Hessl, 2011). The cognitive and the behavioural descriptions are two views of the same underlying weakness in executive control.

Genetics and the Repeat Expansion

Fragile X syndrome is caused by the expansion of a *CGG trinucleotide repeat* in the 5′ untranslated region of the FMR1 gene. The number of times the three-letter sequence CGG is repeated varies between people, and it is this count that determines the outcome. A normal allele carries roughly 5 to 44 repeats and is transmitted stably; the full mutation of more than 200 repeats silences the gene and causes the syndrome (Verkerk et al., 1991). Crucially, the coding sequence of the gene is not altered — the protein it specifies is normal — so fragile X is a disorder of gene *expression*, not of a broken protein (Pieretti et al., 1991).

Between the normal allele and the full mutation lie two intermediate classes. A *grey-zone* (intermediate) allele of about 45 to 54 repeats makes normal protein and causes no fragile X but is slightly unstable. A *premutation* of about 55 to 200 repeats likewise does not cause fragile X syndrome but is genuinely unstable across generations: when a female carrier transmits it, the repeat can lengthen, sometimes leaping into the full-mutation range in a single generation (Willemsen et al., 2011). This length-dependent instability was what resolved the so-called Sherman paradox — the puzzling observation that the risk of the syndrome rose down the generations of a family — once it was understood that a premutation grows toward a full mutation with each maternal transmission (Fu et al., 1991).

Two features of transmission follow, and both matter clinically. First, expansion from premutation to full mutation happens only through the *mother*: a premutation passed by a father stays a premutation in his daughters. Second, the larger the maternal premutation, the greater the chance it expands to a full mutation — so repeat length is not merely diagnostic but predictive of transmission risk (Willemsen et al., 2011). The interactive spectrum below maps each repeat class to its consequence.

Worked Example

The claim at the heart of the cognitive phenotype — that inhibitory attention is *disproportionately* impaired — is easy to state and easy to test badly, so it is worth making concrete. The trap is to compare a child with fragile X against typically developing children of the *same chronological age*. On that comparison almost everything looks impaired, because the child has a general developmental delay; the comparison simply re-measures the delay and reveals nothing about which abilities are *specifically* affected (Cornish et al., 2004).

The correct comparison is against younger, typically developing children matched on *mental age* — the same move the interactive profile makes by drawing its baseline at “the level expected for mental age” rather than for chronological age. To illustrate the arithmetic, consider a 10-year-old boy with fragile X whose overall mental age is 6. Suppose typically developing 6-year-olds make, on average, 12 errors on an attentional-inhibition task, with a standard deviation of 4. If our boy tracks his mental age on a control task — say, a simultaneous-pattern task on which he too scores near the 6-year-old average — then that ability is *in line* with his general level. But if he makes 24 errors on the inhibition task, his score is (24 − 12) / 4 = 3 standard deviations worse than his own mental-age level.

That gap is the whole point. A deficit that is merely part of the general delay disappears once mental age is matched; a *disproportionate* deficit — like the three-SD shortfall in inhibition here — survives the match and stands out as specific to the syndrome. Expressed on the interactive profile's scale, where 100 is the mental-age level, the spared simultaneous-processing ability sits above the line while inhibitory attention falls far below it. The lesson is methodological: whether an impairment is “characteristic” of a syndrome is a claim about a comparison, and only the mental-age-matched comparison can support it (Munir et al., 2000).

Attention and Memory

If the syndrome has a cognitive centre of gravity, it is the control of attention. Across tasks, children with fragile X have particular difficulty *inhibiting* an automatic or prepotent response and *sustaining* controlled attention in the face of distraction, while more automatic, stimulus-driven orienting is comparatively intact (Munir et al., 2000). This is why the deficit is best described as one of *executive* attention — the top-down, effortful control of what to attend to and what to suppress — rather than a general inability to attend at all (Cornish et al., 2004).

Working memory is tightly bound up with this. Holding information in mind over a few seconds while resisting interference draws on exactly the executive-attention resources the syndrome impairs, so working-memory tasks reveal the deficit clearly, and the shortfall grows as the load and the demand for control increase (Cornish et al., 2013). Longitudinal work tracking the same children over years has asked whether this is a fixed deficit or a *developmental* one, and finds the latter: attention and working memory do not simply stall but follow an altered trajectory, so the gap from typically developing peers changes shape across childhood rather than staying constant (Cornish et al., 2013).

The attentional and executive weaknesses also interact with the emotional side of the phenotype. Social anxiety, gaze avoidance, and heightened arousal are common, and they both draw on and further tax the same limited resources for regulating attention and response — a convergence of cognitive and affective difficulty that is characteristic of the syndrome and consequential for everyday functioning (Cordeiro et al., 2011).

Neurobiology

The path from the expanded repeat to the altered mind runs through a well-worked-out molecular cascade. The full-mutation repeat triggers *methylation* of the FMR1 promoter — a chemical mark that closes the gene — so that the gene, though structurally intact, is no longer transcribed (Sutcliffe et al., 1992). With the gene silenced, its product, the fragile X messenger ribonucleoprotein (FMRP), is not made (Pieretti et al., 1991). FMRP is an RNA-binding protein that travels to the synapse and acts as a *brake* on the local translation of many messenger RNAs; without it, that brake is released (Santoro, Bray, & Warren, 2012).

The consequence at the synapse is the core of the modern account. When FMRP is absent, protein synthesis downstream of group-1 metabotropic glutamate receptors (mGluR5) runs unchecked, a form of synaptic weakening called long-term depression is exaggerated, and dendritic spines remain long, thin, and immature rather than maturing into stable connections (Santoro et al., 2012). This immature-spine morphology was seen directly in the fragile X knockout mouse, whose cortical neurons carry abnormally long, dense, immature spines (Comery et al., 1997). The idea that exaggerated mGluR-driven translation explains the synaptic and behavioural phenotype — the mGluR theory — became the field's central mechanistic hypothesis and the rationale for a generation of drug trials (Bagni & Zukin, 2019).

More recent molecular work has enriched this picture rather than overturning it, detailing the many classes of synaptic messenger RNA that FMRP regulates and how their dysregulation ties fragile X to the broader biology of autism spectrum disorders and synaptic plasticity (Richter & Zhao, 2021). Structural neuroimaging complements the cellular story: the brain in fragile X shows characteristic regional differences, including in the caudate and in structures supporting attention and memory, consistent with the executive-attention phenotype (Reiss, Lee, & Freund, 1994). The interactive cascade below steps through the sequence from repeat to synapse.

Development Across the Lifespan

Fragile X is a developmental condition, and its cognitive profile is best understood as a *trajectory* rather than a fixed state. In early childhood the differences from typical development can be relatively subtle, but the *rate* of cognitive growth is slower, so measured IQ expressed relative to chronological age tends to decline through childhood even as absolute abilities keep growing (Cornish et al., 2013). The uneven profile itself sharpens over development: the gap between the spared and the impaired systems, and the prominence of the executive-attention deficit, becomes more marked with age, which is why a *developmental* framework is essential rather than optional (Loesch et al., 2004).

This developmental view carries a warning against over-generalising, because there is wide *individual variability*. The amount of residual FMRP is not all-or-none — it varies with the degree of methylation and, in females, with X-inactivation — and the level of protein correlates with the severity of the cognitive profile, so two people with a full mutation can differ considerably (Loesch et al., 2004). The profile describes a central tendency, not a template, and outcomes in language, attention, and adaptive behaviour differ widely for reasons that include protein level, sex, health comorbidities, and environment (Raspa, Wheeler, & Riley, 2017).

Across the lifespan the practical needs shift from early developmental and educational support to adult independence, employment, and mental health, and the public-health literature emphasises how much of the burden is bound up with treatable co-occurring conditions — anxiety, attention problems, sleep, and seizures among them (Raspa et al., 2017). Recognising fragile X as a lifespan condition, not only a childhood one, has become central to how services are planned.

The Premutation Disorders

One of the most important modern insights is that the *premutation* — the 55-to-200-repeat allele that does not cause fragile X syndrome — is not silent. It carries its own, quite separate risks, and by a different mechanism. Where the full mutation silences the gene and works by *loss* of FMRP, the premutation leaves the gene active but produces elevated levels of FMR1 messenger RNA, and it is this excess RNA that appears to be toxic — a *gain*-of-function mechanism rather than a loss (Santoro et al., 2012).

Two conditions follow. *Fragile X–associated tremor/ataxia syndrome* (FXTAS) is a late-onset neurodegenerative disorder — tremor, gait ataxia, and cognitive decline — seen mainly in older male premutation carriers. *Fragile X–associated primary ovarian insufficiency* (FXPOI) is early ovarian decline in female carriers. Neither is fragile X syndrome, and neither carrier need have any intellectual disability, yet both flow from the same premutation allele (Willemsen et al., 2011). The clinical upshot is that a single family can contain, across its members and generations, a full-mutation child with the syndrome, a premutation grandfather with tremor and ataxia, and a premutation mother with early menopause — three very different presentations of one gene.

This has reframed genetic counselling and screening. Because a premutation is common, transmissible, expandable, and consequential in its own right, identifying carriers matters for far more than the risk of an affected child, and it complicates the ethics of population screening (Hagerman et al., 2017).

Discussion

The scientific importance of fragile X syndrome for cognitive psychology rests on the idea running through everything above: the loss of a single protein produces not a uniform lowering of the mind but a *structured*, dissociable profile with a specific deficit at its centre. That a disorder of one gene should so selectively impair inhibitory and executive attention, while sparing simultaneous processing and meaningful memory, is evidence that these are separable systems — the kind of dissociation, obtained from a genetic experiment, that laboratory studies of attention can only approximate (Cornish et al., 2004; Munir et al., 2000).

Fragile X also became a proving ground for reasoning from gene to mind and back. The mGluR theory made the prediction that dialling down mGluR5 signalling should correct the synaptic and behavioural phenotype, and that prediction drove targeted clinical trials — a rare case of a psychiatric-neurodevelopmental treatment reasoned out from molecular mechanism rather than found by chance (Bagni & Zukin, 2019). That those trials have so far largely failed to show clinical benefit is itself instructive: it has forced a reckoning with how mouse-model success translates to humans, with outcome measurement, and with developmental timing, and has reshaped how the whole field approaches drug development for neurodevelopmental disorders (Berry-Kravis et al., 2018).

Cognitive Implications

For cognitive psychology, fragile X is a standing demonstration that the control of attention is a distinct, fractionable component of the mind. The disproportionate impairment of inhibitory and executive attention, against relatively spared automatic orienting, supports the view that executive function is separable from attention in general — a distinction drawn in the laboratory and here confirmed by a genetic dissociation (Cornish et al., 2004). The bound-up weakness in working memory shows the same, tying the syndrome's profile to the executive, control-demanding aspects of holding information in mind (Cornish et al., 2013).

The syndrome-profile method it exemplifies has become general in the study of intelligence and learning disabilities: different genetic conditions produce different cognitive signatures, and comparing them helps establish which components are genuinely separable and how they map onto brain systems (Munir et al., 2000). The practical payoff is educational. Recognising that a learner has relative strengths in simultaneous processing and meaningful memory, and a specific weakness in sequential processing and executive attention, allows teaching to lean on the strengths — presenting material as meaningful wholes rather than as sequences to be held and manipulated under executive load (Raspa et al., 2017).

Current Directions

Much current research follows from the disappointment of the first targeted trials. The mGluR5 antagonist mavoglurant, despite a strong mechanistic rationale and success in mice, did not improve behaviour in randomized, placebo-controlled trials in adolescents and adults — a result that turned attention to whether such treatments must be given far earlier in development, whether the outcome measures were sensitive enough, and whether patient stratification by methylation status is needed (Berry-Kravis et al., 2016). The broader lesson — how to carry a molecular target through to a demonstrated clinical benefit in a neurodevelopmental disorder — has itself become a field of study (Berry-Kravis et al., 2018).

At the molecular level, work continues to map the full set of messenger RNAs that FMRP regulates and to connect their dysregulation to the wider biology of synaptic plasticity and autism, opening potential targets beyond mGluR5 (Richter & Zhao, 2021). Alongside the search for treatments runs the older clinical programme of managing the condition well — treating the anxiety, attention, and behavioural difficulties that most affect daily life — and refining when and whom to screen, given the separate consequences of the premutation (Hagerman et al., 2009). Across all of these, the field increasingly frames fragile X as a developmental trajectory whose course might be altered, rather than a fixed deficit to be catalogued (Cornish et al., 2013).

Common Misconceptions

“Fragile X lowers all abilities equally.”

It does not. The defining cognitive feature is an uneven profile with a disproportionate deficit in inhibitory and executive attention, against relative strengths in simultaneous processing and meaningful memory (Cornish et al., 2004; Munir et al., 2000).

“A premutation is just a mild version of fragile X syndrome.”

No. A premutation does not cause fragile X syndrome at all; it works by a different, RNA-toxic mechanism and carries separate risks (FXTAS and FXPOI). Its importance is that it can expand to a full mutation when a mother passes it on (Willemsen et al., 2011; Santoro et al., 2012).

“The FMR1 gene is broken in fragile X.”

The gene's protein-coding sequence is normal. Fragile X is a disorder of expression: the expanded repeat causes the promoter to be methylated and the intact gene to be switched off, so no protein is made (Pieretti et al., 1991; Sutcliffe et al., 1992).

“Only boys are affected.”

Females can be affected too. Because they have a second X chromosome and random X-inactivation, they are affected more variably and usually more mildly, but not spared (Loesch et al., 2004).

Glossary

CGG repeat.

A three-letter DNA sequence (cytosine-guanine-guanine) repeated a variable number of times at the start of the FMR1 gene; its length determines whether fragile X syndrome occurs.

Cognitive phenotype.

The characteristic profile of cognitive strengths and weaknesses associated with a genetic condition; in fragile X, an uneven pattern centred on an executive-attention deficit.

Executive attention.

The top-down, effortful control of attention and response, including inhibition; the domain most disproportionately impaired in fragile X.

FMR1 gene.

The gene on the X chromosome whose silencing causes fragile X syndrome; it encodes the protein FMRP.

FMRP.

Fragile X messenger ribonucleoprotein, an RNA-binding protein that acts as a brake on local protein synthesis at the synapse; its absence produces the syndrome.

Full mutation.

An FMR1 allele of more than about 200 CGG repeats; it triggers methylation and gene silencing and causes fragile X syndrome.

FXPOI.

Fragile X–associated primary ovarian insufficiency; early ovarian decline in female premutation carriers.

FXTAS.

Fragile X–associated tremor/ataxia syndrome; a late-onset neurodegenerative disorder in older premutation carriers, driven by toxic FMR1 mRNA rather than loss of protein.

Grey-zone allele.

An intermediate allele of about 45–54 CGG repeats; it makes normal protein and causes no fragile X but is mildly unstable.

Loss of function.

A mechanism in which a gene's product is missing or reduced; fragile X syndrome is a loss-of-function disorder because the silenced gene makes no FMRP.

Methylation (epigenetic silencing).

A chemical mark on DNA that closes a gene's promoter; in fragile X the expanded repeat recruits methylation that switches FMR1 off.

mGluR theory.

The proposal that, without FMRP, protein synthesis downstream of group-1 metabotropic glutamate receptors runs unchecked, producing exaggerated synaptic depression and immature dendritic spines.

Premutation.

An FMR1 allele of about 55–200 CGG repeats; unstable and expandable to a full mutation through maternal transmission, and itself a risk for FXTAS and FXPOI.

Trinucleotide repeat expansion.

The growth of a repeated three-base DNA unit beyond its normal range across generations; the class of genetic change underlying fragile X.

Working memory.

The system for holding and manipulating information over seconds; disproportionately impaired in fragile X because of its heavy executive-attention demands.

X-linked inheritance.

Inheritance of a gene on the X chromosome; it explains why males, with one X, are more consistently and severely affected by fragile X than females, who have two.

Key Researchers

Mark F. Bear

(living). A neuroscientist at the Picower Institute for Learning and Memory, MIT, whose work on synaptic plasticity underlies the mGluR theory of fragile X; co-author of the influential 2004 paper proposing that account. ORCID

Elizabeth Berry-Kravis

(living). A physician-scientist at Rush University Medical Center who has led the major clinical trials in fragile X, including the mavoglurant studies, and shaped thinking on drug development for the syndrome. ORCID

Kim Cornish

(living). A psychologist at Monash University whose developmental-neuropsychological work deconstructed the attention deficit in fragile X and traced its trajectory across childhood. ORCID

Randi J. Hagerman

(living). A developmental-behavioural pediatrician at the MIND Institute, University of California, Davis, who has led the clinical characterization and treatment of fragile X across the lifespan. ORCID

David L. Nelson

(living). A human geneticist at Baylor College of Medicine, a co-discoverer of the FMR1 gene and of the CGG-repeat expansion that causes fragile X. ORCID

Stephen T. Warren

(1953–2021). A geneticist at Emory University who led the team that cloned FMR1 and identified the CGG-repeat expansion in 1991, founding the molecular understanding of the syndrome. Wikidata

Frequently Asked Questions

What causes fragile X syndrome?

It is caused by expansion of a CGG repeat in the FMR1 gene past about 200 copies. The expanded repeat causes the gene's promoter to be methylated and switched off, so the gene's protein, FMRP, is not made (Verkerk et al., 1991; Sutcliffe et al., 1992).

Is fragile X syndrome inherited?

Yes — it is the most common inherited cause of intellectual disability. The unstable repeat is passed down and can expand from a premutation to a full mutation when transmitted by the mother (Fu et al., 1991; Willemsen et al., 2011).

What is the cognitive signature of fragile X?

An uneven profile whose hallmark is a disproportionate deficit in inhibitory and executive attention, with weaknesses in sequential processing and working memory against relative strengths in simultaneous processing, receptive vocabulary, and meaningful memory (Cornish et al., 2004).

Are girls affected as well as boys?

Yes, but usually more mildly and more variably. Females have a second X chromosome, and random X-inactivation leaves some working copies of the gene, so the effect is diluted (Loesch et al., 2004).

What is a premutation?

An FMR1 allele of about 55–200 CGG repeats. It does not cause fragile X syndrome but is unstable, can expand to a full mutation in the next generation, and carries separate risks of tremor/ataxia (FXTAS) and early ovarian insufficiency (FXPOI) (Willemsen et al., 2011).

How is fragile X related to autism?

It is the most common known single-gene cause of autism, and its underlying synaptic biology — excess protein synthesis and immature dendritic spines — overlaps with the wider biology of autism spectrum disorders (Bagni & Zukin, 2019; Richter & Zhao, 2021).

Is there a treatment?

There are treatments for the associated difficulties — anxiety, attention, behaviour — but no approved treatment that reverses the core condition. Targeted trials based on the mGluR theory have so far not shown clinical benefit, reshaping how the field pursues such treatments (Berry-Kravis et al., 2016; Berry-Kravis et al., 2018).

Why does fragile X matter to cognitive psychology?

Because the loss of a single protein produces a specific, dissociable cognitive deficit — disproportionately in executive attention — which is strong evidence that attentional control is a separable component of the mind (Cornish et al., 2004; Munir et al., 2000).

Support Organizations

• National Fragile X Foundation — advocacy, family support, and community resources for fragile X conditions in the United States.
• FRAXA Research Foundation — funds research toward treatments and a cure for fragile X syndrome.
• Fragile X Association of Australia — support, information, and advocacy for families affected by fragile X.
• Fragile X Society (UK) — information and support for people with fragile X and their families in the United Kingdom.

References

Sutherland, G. R., & Hinton, L. (1981). Heritable fragile sites on human chromosomes. Human Genetics, 57(2), 217–219. https://doi.org/10.1007/bf00282028

Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., … Warren, S. T. (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell, 65(5), 905–914. https://doi.org/10.1016/0092-8674(91)90397-H

Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., & Nelson, D. L. (1991). Absence of expression of the FMR-1 gene in fragile X syndrome. Cell, 66(4), 817–822. https://doi.org/10.1016/0092-8674(91)90125-i

Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Pieretti, M., Sutcliffe, J. S., Richards, S., … Caskey, C. T. (1991). Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox. Cell, 67(6), 1047–1058. https://doi.org/10.1016/0092-8674(91)90283-5

Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., & Warren, S. T. (1992). DNA methylation represses FMR-1 transcription in fragile X syndrome. Human Molecular Genetics, 1(6), 397–400. https://doi.org/10.1093/hmg/1.6.397

Reiss, A. L., Lee, J., & Freund, L. (1994). Neuroanatomy of fragile X syndrome: The temporal lobe. Neurology, 44(7), 1317–1324. https://doi.org/10.1212/wnl.44.7.1317

Comery, T. A., Harris, J. B., Willems, P. J., Oostra, B. A., Irwin, S. A., Weiler, I. J., & Greenough, W. T. (1997). Abnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits. Proceedings of the National Academy of Sciences, 94(10), 5401–5404. https://doi.org/10.1073/pnas.94.10.5401

Munir, F., Cornish, K. M., & Wilding, J. (2000). A neuropsychological profile of attention deficits in young males with fragile X syndrome. Neuropsychologia, 38(9), 1261–1270. https://doi.org/10.1016/s0028-3932(00)00036-1

Cornish, K., Turk, J., Wilding, J., Sudhalter, V., Munir, F., Kooy, F., & Hagerman, R. (2004). Annotation: Deconstructing the attention deficit in fragile X syndrome: A developmental neuropsychological approach. Journal of Child Psychology and Psychiatry, 45(6), 1042–1053. https://doi.org/10.1111/j.1469-7610.2004.t01-1-00297.x

Loesch, D. Z., Huggins, R. M., & Hagerman, R. J. (2004). Phenotypic variation and FMRP levels in fragile X. Developmental Disabilities Research Reviews, 10(1), 31–41. https://doi.org/10.1002/mrdd.20006

Coffee, B., Keith, K., Albizua, I., Malone, T., Mowrey, J., Sherman, S. L., & Warren, S. T. (2009). Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. The American Journal of Human Genetics, 85(4), 503–514. https://doi.org/10.1016/j.ajhg.2009.09.007

Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., … Tranfaglia, M. (2009). Advances in the treatment of fragile X syndrome. Pediatrics, 123(1), 378–390. https://doi.org/10.1542/peds.2008-0317

Willemsen, R., Levenga, J., & Oostra, B. A. (2011). CGG repeat in the FMR1 gene: Size matters. Clinical Genetics, 80(3), 214–225. https://doi.org/10.1111/j.1399-0004.2011.01723.x

Cordeiro, L., Ballinger, E., Hagerman, R., & Hessl, D. (2011). Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: Prevalence and characterization. Journal of Neurodevelopmental Disorders, 3(1), 57–67. https://doi.org/10.1007/s11689-010-9067-y

Santoro, M. R., Bray, S. M., & Warren, S. T. (2012). Molecular mechanisms of fragile X syndrome: A twenty-year perspective. Annual Review of Pathology: Mechanisms of Disease, 7(1), 219–245. https://doi.org/10.1146/annurev-pathol-011811-132457

Cornish, K., Cole, V., Longhi, E., Karmiloff-Smith, A., & Scerif, G. (2013). Mapping developmental trajectories of attention and working memory in fragile X syndrome: Developmental freeze or developmental change? Development and Psychopathology, 25(2), 365–376. https://doi.org/10.1017/s0954579412001113

Hunter, J., Rivero-Arias, O., Angelov, A., Kim, E., Fotheringham, I., & Leal, J. (2014). Epidemiology of fragile X syndrome: A systematic review and meta-analysis. American Journal of Medical Genetics Part A, 164(7), 1648–1658. https://doi.org/10.1002/ajmg.a.36511

Berry-Kravis, E., Des Portes, V., Hagerman, R., Jacquemont, S., Charles, P., Visootsak, J., … von Raison, F. (2016). Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials. Science Translational Medicine, 8(321), 321ra5. https://doi.org/10.1126/scitranslmed.aab4109

Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., … Hagerman, P. J. (2017). Fragile X syndrome. Nature Reviews Disease Primers, 3(1), 17065. https://doi.org/10.1038/nrdp.2017.65

Raspa, M., Wheeler, A. C., & Riley, C. (2017). Public health literature review of fragile X syndrome. Pediatrics, 139(Suppl. 3), S153–S171. https://doi.org/10.1542/peds.2016-1159C

Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., … Jacquemont, S. (2018). Drug development for neurodevelopmental disorders: Lessons learned from fragile X syndrome. Nature Reviews Drug Discovery, 17(4), 280–299. https://doi.org/10.1038/nrd.2017.221

Bagni, C., & Zukin, R. S. (2019). A synaptic perspective of fragile X syndrome and autism spectrum disorders. Neuron, 101(6), 1070–1088. https://doi.org/10.1016/j.neuron.2019.02.041

Richter, J. D., & Zhao, X. (2021). The molecular biology of FMRP: New insights into fragile X syndrome. Nature Reviews Neuroscience, 22(4), 209–222. https://doi.org/10.1038/s41583-021-00432-0